This Day On The Street
Continue to site right-arrow
ADVERTISEMENT
This account is pending registration confirmation. Please click on the link within the confirmation email previously sent you to complete registration.
Need a new registration confirmation email? Click here
TheStreet Open House

Galena Biopharma Poster Presentation At The American Pain Society 32nd Annual Scientific Meeting

Stocks in this article: GALE

  • Abstral ® (fentanyl) Sublingual Tablets are an important new treatment option for inadequately controlled breakthrough cancer pain (BTcP) which impacts the majority of cancer patients at some point in their care.
  • Abstral, the first and only sublingual fentanyl tablet for BTcP, TIRF REMS serves as model program.

LAKE OSWEGO, Ore., May 9, 2013 (GLOBE NEWSWIRE) -- Galena Biopharma, Inc. (Nasdaq:GALE), a biopharmaceutical company developing innovative, targeted oncology treatments that address major unmet medical needs to advance cancer care, presented information on the development of a Transmucosal Immediate Release Fentanyl (TIRF) REMS program at the American Pain Society 32 nd Annual Scientific Meeting. The event is being held May 8-11, 2013 at the Ernest N. Morial Convention Center in New Orleans, Louisiana.

The poster presentation entitled: "Development of a Federally Mandated Risk Evaluation and Mitigation Strategy (REMS) for Transmucosal Immediate-Release Fentanyl Products" describes the development and implementation of the now fully implemented TIRF REMS program for this important class of drug. The poster concluded that the TIRF REMS program is an important step toward the Food and Drug Administration Amendments Act (FDAAA) goals to reduce misuse, abuse, addiction, overdose, and medication-related errors. The shared TIRF REMS program streamlines the process to safely provide appropriate patients with various forms of TIRF medications, and points out that the goals of the TIRF REMS program need to be balanced against the potential for untreated or poorly treated pain. The complex nature of these goals requires collaboration amongst prescribers, pharmacies, distributors, and patients to achieve optimal success.

"Abstral is a significant advance for patients with breakthrough cancer pain and the TIRF REMS program is an essential element to prescribing Abstral® to ensure that patients are safely and effectively treated," stated Mark J. Ahn, Ph.D., Galena's President and Chief Executive Officer. "Abstral's sublingual TIRF REMS program served as a model for the current shared TIRF REMS, and we look forward to launching our product in the U.S. this year."

1 of 2

Check Out Our Best Services for Investors

Action Alerts PLUS

Jim Cramer and Stephanie Link reveal their investment tactics while giving advanced notice before every trade.

Product Features:
  • $2.5+ million portfolio
  • Large-cap and dividend focus
  • Intraday trade alerts from Cramer
Quant Ratings

Access the tool that DOMINATES the Russell 2000 and the S&P 500.

Product Features:
  • Buy, hold, or sell recommendations for over 4,300 stocks
  • Unlimited research reports on your favorite stocks
  • A custom stock screener
Stocks Under $10

Jim Cramer's protégé, David Peltier, uncovers low dollar stocks with extraordinary upside potential that are flying under Wall Street's radar.

Product Features:
  • Model portfolio
  • Stocks trading below $10
  • Intraday trade alerts
Try it NOW
Try it NOW
Try it NOW

Check Out Our Best Services for Investors

Dividend Stock Advisor

Jim Cramer's protégé, David Peltier, identifies the best of breed dividend stocks that will pay a reliable AND significant income stream.

Product Features:
  • Diversified model portfolio of dividend stocks
  • Updates with exact steps to take - BUY, HOLD, SELL
Trifecta Stocks

Every recommendation goes through 3 layers of intense scrutiny—quantitative, fundamental and technical analysis—to maximize profit potential and minimize risk.

Product Features:
  • Model Portfolio
  • Intra Day Trade alerts
  • Access to Quant Ratings
Options Profits

Our options trading pros provide over 100 monthly option trading ideas and strategies to help you become a well-seasoned trader.

Product Features:
  • Actionable options commentary and news
  • Real-time trading community
Try it NOW
Try it NOW
Try it NOW
To begin commenting right away, you can log in below using your Disqus, Facebook, Twitter, OpenID or Yahoo login credentials. Alternatively, you can post a comment as a "guest" just by entering an email address. Your use of the commenting tool is subject to multiple terms of service/use and privacy policies - see here for more details.
Submit an article to us!

Markets

DOW 17,164.95 -251.90 -1.45%
S&P 500 1,994.99 -26.26 -1.30%
NASDAQ 4,635.24 -48.1670 -1.03%

Partners Compare Online Brokers

Free Reports

Free Newsletters from TheStreet

My Subscriptions:

After the Bell

Before the Bell

Booyah! Newsletter

Midday Bell

TheStreet Top 10 Stories

Winners & Losers

Register for Newsletters
Top Rated Stocks Top Rated Funds Top Rated ETFs